Abstract
Prostate cancer is an enigmatic disease. Although prostatic-intraepithelial neoplasia appears as early as the third decade and as many as 80% of 80 year old men have epithelial cells in their prostate that fit the morphological criteria for cancer, only about 10% of men will ever have the clinical disease and less than 3% will die from it. There have been no significant proven interventions which have altered the natural history of the disease since hormone down regulation was introduced in the 1940s and new research has been poorly supported. There is however an urgent need to develop new criteria to distinguish those patients with localised disease who will benefit from intervention from those that do not require it or who will have occult extra prostatic metastases. Similarly, there is an urgent need to develop new treatment for those in whom the disease is extra-prostatic and therefore incurable by conventional treatments. This review covers the latest developments in epidemiology, cellular and molecular biology including new areas such as ion channels in the field of prostate cancer.
Similar content being viewed by others
References
Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. [Review]. N Engl J Med 333: 1401–1405, 1995
Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54: 594–606, 1993
Boyle P, Maisonneuve P, Napalkov P: Incidence of prostate cancer will double by the year 2030: the argument for. Eur Urol 29(Suppl 2): 3–9, 1996
Jensen OM, Esteve J, Moller H, Renard H: Cancer in the European Community and its member states. Eur J Cancer 25: 1167–1256, 1990
Boring CC, Squires TS, Tong T: Cancer Statistics CA. Cancer J Clin 44: 7–26, 1994
Boyle P, Maisonneuve P, Napalkov P: The threat to health and strategies for control. In: Peeling WB (ed) Questions and Uncertainties about Prostate Cancer, pp. 3–29, Oxford: Blackwell Science, 1996
Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics 1996, CA, Cancer J Clin 1996
Schroder FH, Boyle P: Screening for prostate cancer — necessity or nonsense? [Review] Eur J Cancer 29A: 656–661, 1993
Potosky AL, Miller BA, Albertsen PC, Kramer BS: The role of increasing detection in the rising incidence of prostate cancer. JAMA 273: 548–552, 1995
Walsh PC: Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters [editorial; comment] [see comments]. Ann Intern Med 119: 948–949, 1993
Hall RR: Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Eur Urol 29(Suppl 2): 24–26, 1996
Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119: 914–923, 1996
Haenszel W, Kurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. Natl Cancer Inst Monogr 40: 43–68, 1996
Anonymous: Primer on molecular control of prostate cancer growth. New Jersey: Whitchouse Station, Merck, 1994
Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CC, Willett WCA: A prospective study of dietary fat and risk of prostate cancer [see comments]. J Natl Cancer Inst 85: 1571–1579, 1993
The alpha-tocopherol, beta-carotene cancer prevention study group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330: 1029–1035, 1994
Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N: Vitamin D and prostate cancer: a prediagnostic study with stored sera [see comments]. Cancer Epidemiol Biomarkers Prev 2: 467–472, 1993
Morrison H, Savitz D, Semenciw R, Hulka B, Mao Y, Morison D, Wigle D: Farming and prostate cancer mortality [see comments]. Am J Epidemiol 137: 270–280, 1993
Dosemeci M, Hoover RN, Blair A, Figgs LW, Devesa S, Grauman D, Fraumeni JF Jr: Farming and prostate cancer among African-Americans in the southeastern United States. J Natl Cancer Inst 86: 1718–1719, 1994
Ekbom A, Hsieh CC, Lipworth L, Wolk A, Ponten J, Adam HO, Trichopoulos D: Perinatal characteristics in relation to incidence of and mortality from prostate cancer. Br Med J 313: 337–341, 1996
Whitmore WF Jr: Natural history of low-stage prostatic cancer and the impact of early detection. Urol Clin North Am 17: 689–697, 1990
Young HH: The early diagnosis and radical cure of carcinoma of the prostate; being a study of 40 cases and presentation of a radical operation which was carried out in 4 cases. Bull Johns Hopkins Hosp 16: 315–318, 1905
Lu-Yao GL, Greenberg ER: Changes in prostate cancer incidence and treatment in USA [see comments]. Lancet 343: 251–254, 1994
Williams G: Radical prostatectomy in localised prostate cancer. In: Waxman J, Williams G (eds) Urological Oncology, London: Edward Arnold, 1992
Breslow N, Chan CE, Dhom G, Drury RAB, Frank LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H: Latent carcinoma of the prostate at autopsy in 7 areas. Int J Cancer 20: 680–688, 1996
Schroder FH: Detection of prostate cancer [editorial] [see comments]. Br Med J 310: 140–141, 1995
Ayala AG, Ro JY, Babaian R, Troncoso P, Grignon DJ: The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13: 21–27, 1989
McNeal JE: Normal histology of the prostate. Am J Surg Pathol 12: 619–633, 1988
McNeal JE, Bostwick DG: Anatomy of the prostate: implications for disease. In: Bostwick DG (ed) Pathology of the Prostate, pp. 1–14, New York: Churchill Livingstone, 1990
McNeal JE: Origin and development of carcinoma in the prostate. Cancer 23: 24–34, 1969
Allsbrook WC Jr, Simms WW: Histochemistry of the prostate [see comments]. [Review]. Hum Pathol 23: 297–305, 1992
Leong AS, Gilham P, Milos J: Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium. Histopathology 13: 435–442, 1988
Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, Van der Kwast TH: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Patiol 144: 735–746, 1994
Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y: The endocrinology and developmental biology of the prostate. [Review]. Endocr Rev 8: 338–362, 1987
Bonkhoff H, Stein U, Remberger K: Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 25: 42–46, 1994
Gown AM, Vogel AM: Monoclonal antibodies to human intermediate filament proteins: distribution of filament proteins in normal human tissues. Am J Pathol 114: 309–321, 1984
Hedrick L, Epstein JI: Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13: 389–396, 1989
O'Malley FP, Grignon DJ, Shum DT: Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 417: 191–196, 1990
Kramer CE, Epstein JI: Nucleoli in low-grade prostate adenocarcinoma and adenosis. Hum Pathol 24: 618–623, 1993
Collina G, Botticelli AR, Martinelli AM, Fano RA, Trentini GP: Sclerosing adenosis of the prostate, Report of 3 cases with electronmicroscopy and immunohistochemical study. Histopathology 20: 505–510, 1992
Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI: Utilization of high molecular weight cytokeratin on prostate needle biopsics in an independent laboratory. Urology 45: 981–986, 1995
Howat AJ, Mills PM, Lyons TJ, Stephenson TJ: Absence of S-100 protein in prostatic glands. Histopathology 13: 468–470, 1988
Srigley JR, Dardick I, Hartwick RW, Klotz LH: Basal epithelial cells of human prostate gland are not myoepithelial cells. A comparative immunohistochemical and ultrastructural study with human salivary gland. Am J Pathol 136: 957–966, 1990
Bonkhoff H, Remberger K: Widespread distribution of nuclear androgen receptor in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch A Pathol Anat Histopathol 422: 35–38, 1993
Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C: Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. J Urol 147: 798–803, 1992
Cohen RJ, Glezerson G, Taylor LF, Grundle HA, Naude JH. The neuroendocrine cell population of the human prostate gland. J Urol 150: 365–368, 1993
Abrahamsson PA, di Sant'Agnese PA: Neuroendocrine cells in the human prostate gland. [Review]. J Androl 14: 307–309, 1993
Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71: 3952–3965, 1993
di Sant'Agnese PA, de Mesy Jensen KL, Churukian CJ, Agarwal MM: Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. Arch Pathol Lab Med 109: 607–612, 1985
Davis NS, di Sant'Agnese PA, Ewing JF, Mooney RA: The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. J Urol 142: 884–888, 1989
Bonkhoff H, Stein U, Remberger K: Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Arch A Pathol Anat Histopathol 423: 291–294, 1993
Noordzij MA, Van Steenbrugge GJ, Van der Kwast TH, Schroder FH: Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate. [Review]. Urol Res 22: 333–341, 1995
di Sant'Agnese PA: Neuroendocrine differentiation in the precursors of prostate cancer. Eur Urol 30: 185–190, 1996
Kabalin JN, Peehl DM, Stamcy TA: Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate 14: 251–263, 1989
Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE: Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. [Review]. Cancer Surv 11: 91–121, 1991
Cunha GR, Chung LWK, Sannon JM, Taguihi O, Fujii H: Hormone induced morphogenesis and growth: role of mesenchymal interactions. Recent Prog Horm Res 39: 559–598, 1993
Cunha GR, Chung LWK: Stromal epithelial interaction. Induction of prostate phenotype in urothelium of testicular feminized (TFm/y) mice. J Steroid Biochem 14: 1317–1312, 1981
Cunha GR: Epithelial stromal interactions in the development of the urogenital tract. Int Rev Cytol 47: 137–194, 1976
Bostwick DG: Is the behaviour of prostate cancer understood? In: Peeling WB (ed) Questions and Uncertainties about Prostate Cancer, pp. 30–49, Oxford: Blackwell Science, 1996
Bostwick DG: Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. Eur Urol 30: 145–152, 1996
Epstein JI, Grignon DJ, Humphrey PA, McNeal JE, Sesterhenn IA, Troncoso P, Wheeler TM: Interobserver reproducibility in the diagnosis of prostatic intraepithelial neoplasia. Am J Surg Pathol 19: 873–886, 1995
Raviv G, Janssen T, Zlotta AR, Descamps F, Verhest A, Schulman CC: Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. J Urol 156: 1050–1055, 1996
Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP: The association of benign prostatic hyperplasia and cancer of the prostate. [Review]. Cancer 70: 291–301, 1992
Bostwick DG: High grade prostatic intraepithelial neoplasia (PIN), the most likely precursor of prostate cancer. Cancer 75: 1823–1836, 1993
Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients [see comments]. J Urol 150: 379–385, 1993
Barctron GB, Vogt T, Blasenbreu S, Lohrs U: Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. Hum Pathol 25: 506–513, 1994
Crissman JD, Sakr WA, Hussein ME, Pontes JE: DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate. Prostate 22: 155–162, 1993
Weinberg DS, Weidner N: Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. Arch Pathol Lab Med 117: 1132–1137, 1993
Arends MJ, Bird CC: Recombinant DNA technology and its diagnostic applications. Histopathology 21: 303–313, 1992
Crocker J: Molecular biology in histopathology. Chichester: John Wiley and Sons, 1994
Grody WW, Gatti RA, Naeim F: Diagnostic molecular pathology. Mod Pathol 2: 553–568, 1989
Rowley JD, Aster JC, Sklar J: The impact of new DNA diagnostic technology on the management of cancer patients. Survey of diagnostic techniques. Arch Pathol Lab Med 117: 1104–1109, 1993
Sklar J: DNA hybridization in diagnostic pathology. Hum Pathol 16: 654–658, 1985
Molecular techniques in diagnostic pathology. Hum Pathol 25: 555–614, 1994
Lee C, Shevrin DH, Kozlowski JM: In vivo and in vitro approaches to study metastasis in human prostatic cancer. [Review]. Cancer Metastasis Rev 12: 21–28, 1993
Isaacs JT, Isaacs WB, Feitz WW, Scheres J: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9: 261–281, 1986
Hedlund TE, Moffatt KA, Miller GJ: Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha. 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137: 1554–1561, 1996
Naghashfar Z, DiPaolo JA, Woodworth CD, Passaniti A: Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and-18DNA. Cancer Lett 100: 47–54, 1996
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of human prostatic carcinoma. Cancer Res 43: 1909–1818, 1983
Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL: Suppression of the malignant phenotype of human prostatic cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 56: 2157–2160, 1996
Hurkadli KS, Lokeshwar B, Sheth AR, Block NL: Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line. Prostate 24: 285–290, 1994
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807–1811, 1994
Furr BJ, Tucker H: The preclinical development of bicalutamide: pharmacodynamics and mechanism of action Urology 47: 13–25; discussion 29–32, 1996
Taplin M-E, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393–1398, 1995
Lee C, Shevrin DH, Kozlowski JM: In vivo and in vitro approaches to study metastasis in human prostatic cancer [Review]. Cancer Metastasis Rev 12: 21–28, 1993
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16–23, 1979
Garde SV, Sheth AR, Porter AT, Pienta KJ: A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate spectic antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett 70: 159–166, 1993
Stearns ME, Wang M, Stearns M: IL-10 blocks collagen IV invasion by ‘invasion stimulating factor’ activated PC-3 MI-cells: upregulation of TIMP-1 expression. Oncol Res 7: 157–163, 1995
Bishop JM: Molecular themes in oncogenesis. Cell 64: 235–248, 1996
Lisitsyn N, Wigler M: Cloning the differences between 2 complex genomes. Science 259: 946–951, 1993
Dong JT, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268: 884–886, 1995
Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland NJ: A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer 72: 946–951, 1995
Innis MA, Gelfand GH, Sninsky JJ, White TJ: PCR protocols, a guide to methods and applications. San Diego, California: Academic Press, 1990
Jackson V: Studies on histone organization in the nucleosome using formaldehyde as a reversible cross-linking agent. Cell 15: 945–954, 1978
Yasui W, Ito H, Tahara E: DNA analysis of archival material and its application to tumour pathology. Diagnostic molecular pathology. A practical approach. Oxford: IRL Press, 1992
Eisenberg M, Chimera JA: Human identification by DNA analysis. Diagnostic molecular pathology. A practical approach. Oxford: IRL Press, 1992
Orita M, Suzuki Y, Sekiya T, Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874–879, 1989
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T: Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 86: 2766–2770, 1989
Gall JG, Parduc ML: Formation and detection of RNA-DNA hyrid molecules in cytological preparations. Proc Natl Acad Sci USA 63: 378–383, 1969
Herrington S, McGee JO: Diagnostic molecular pathology: A practical approach. In: Herrington CS, McGee JO (eds) Principles and Basic Methodology of DNA/RNA Detection by in situ Hybridization, pp. 69–102, Oxford: IRL Press, 1992
Trent JM: Clinical correlations of chromosome change in human solid tumors: the tip of the iceberg? J Natl Cancer Inst 81: 1874–1878, 1989
Sandberg AA, Ture-Carel C, Gemmill RM: Chromosomes in solid tumors and beyond. Cancer Res 48: 1049–1059, 1988
Morrison L, Legator M: Multicolor in situ hybridisation using direct labelled fluorescent probes. Clin Chem 39: 733–734, 1993
Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson-Keller JJ, Lieber MM, Jenkins RB: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res 54: 3998–4002, 1994
Mullis KB, Faloona FA: Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 155: 335–350, 1987
McPherson MJ, Quirke P, Taylor GR (eds): PCR, A practical approach. Oxford: IRL Press, 1991
Brothman AR, Peehl DM, Patel AM, McNeal JE: Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50: 3795–3803, 1990
Konig H, Tenbel W, Van Dongen IW, Hagemeijer A, Romijn JC, Schroder FH: Tissue culture loss of ancuploid cells from carcinomas of the prostate. Genes Chromosom Cancer 8: 22–27, 1993
Micale MA, Mohamed A, Sakr W, Powell IJ, Wolman SR: Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. Cancer Genel Cytogenet 61: 165–173, 1992
Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, von Eschenbach AC, Chung LW, Liang JC: Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosom Cancer 9: 19–27, 1994
Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thiobideau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 55: 4114–4119, 1995
Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87: 8751–8755, 1990
Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP: Allelotyping of human prostatic adenocarcinoma. Genomics 11: 530–536, 1991
Bergerheim US, Kunimi K, Collins VP, Ekman P: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosom Cancer 3: 215–220, 1991
Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC et al.: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53: 3869–3873, 1993
MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R: Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosom Cancer 10: 151–159, 1994
Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE: Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 54: 3824–3830, 1994
Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Srup SE, Duray PH: Analysis of 99 microdissected prostate carcinomas reves a high frequency of allelic loss on chromosome 8p 12–21. Cancer Res 56: 24111–24126, 1996
Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM: Allelic loss on chromosome 8p12–21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 55: 2959–2962, 1995
Trapman J, Sleddens HF, Van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, Faber PW, Bosman FT: Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54: 6061–6064, 1994
Brothman AR, Patel AM: Characterization of 10 marker chromosomes in a prostatic cancer cell line by in situ hybridization. Cytogenet Cell Genet 60: 8–11, 1992
Murakami YS, Albertsen H, Brothman AR, Leach RJ, White RL: Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. Cancer Res 56: 2157–2160, 1996
Deitch AD, De Vere White RW: Flow cytometry as a predictive modality in prostate cancer. [Review]. Hum Pathol 23: 352–359, 1992
Tribukait B: Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasms. World J Urol 5: 108–122, 1996
Falkmer UG: Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. [Review]. Hum Pathol 23: 360–367, 1992
Jones EC, McNeal J, Bruchovsky N, De Jong G: DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage Gleason grade 4 and 5, and lymph node metastases. Cancer 66: 752–757, 1990
Bos JL: Ras oncogenes in human prostate: review. Cancer Res 49: 4682–4689, 1989
Barbacid M: Ras oncogenes: their role in neoplasia. Eur J Clin Invest 20: 225–235, 1990
Peehl DM: Oncogenes in prostate cancer. An update. [Review]. Cancer 71: 1159–1164, 1993
McCormick F: Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 4: 71–76, 1994
Pergolizzi RG, Kreis W, Rottach C, Susin M, Broome JD: Mutational status of codons 12 and 13 of the N-and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas [see comments]. Cancer Invest 11: 25–32, 1993
Peehl DM, Wehner N, Stamey TA: Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 10: 281–289, 1987
Tsujii T, Yonese J, Kojima S, Tari K, Ishii M, Seino Y: [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. [Japanese]. Nippon Hinyokika Gakkai Zasshi 81: 829–834, 1990
Gumerlock PH, Poonamallee UR, Meyers FJ, De Vere White RW: Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 51: 1632–1637, 1991
Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM: K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 69: 2293–2299, 1992
Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M: Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 52: 5991–5996, 1992
Moul, Theune SM, Chang EH: Detection of ras mutations in archival testicular germ cell tumours by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosom Cancer 5: 109–118, 1992
Voeller HJ, Wilding G, Gelmann EP: v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol Endocrinol 5: 209–216, 1991
Treiger B, Isaacs J: Expression of a transfected v-Harveyras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 140: 1580–1586, 1988
Schalken JA, Ebeling SB, Isaacs JT, Treiger B, Bussemakers MJ, de Jon ME, Van de Ven WJ: Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. Cancer Res 48: 2042–2046, 1988
Partin AW, Isaacs JT, Treiger B, Coffey DS: Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res 48: 6050–6053, 1988
Carter BS, Epstein JI, Isaacs WB: Ras gene mutations in human prostate cancer. Cancer Res 50: 6830–6832, 1990
Viola MV, Fromowitz E, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314: 133–137, 1986
Sumiya H, Masai M, Akimoto S, Yatani R, Shimazaki J: Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. Eur J Cancer 26: 786–789, 1990
Vaima VA, Austin GE, O'Connell AC: Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. Arch Pathol Lab Med 113: 16–19, 1989
Bussemakers MJ, Isaacs JT, Debruyne FMJ, Van der Ven WJM, Schalken JA: Oncogene expression in prostate cancer. World J Urol 9: 58–63, 1991
Cooke DB, Quarmby VE, Petrusz P, Mickey DD, Der CJ, Isaacs JT, French FS: Expression of ras proto-oncogenes in the Dunning R3327 rat prostatic adenocarcinoma system. Prostate 13: 273–287, 1988
Kato GJ, Barret J, Villa Garcia M, Dang C: An amino terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10: 5914–5920, 1990
Escort C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest M, Callahan R: Genetic alterations of the c-myc proto-oncogene in human primary breast carcinoma. Proc Natl Acad Sci USA 83: 4834, 1986
Fleming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ: Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyporplasia. Cancer Res 46: 1535–1538, 1986
Phillips ME, Ferro MA, Smith PJ, Davies P: Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. Urol Int 42: 115–119, 1987
Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11: 327–337, 1987
Cooke DB, Quarmby VE, Mickey DD, Isaacs JT, French FS: Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate 13: 263–272, 1988
Eaton CL, Davies P, Phillips ME: Growth factor involvement and oncogene expression in prostatic tumours. J Steroid Biochem 30: 341–345, 1988
Matusik RJ, Fleming WH, Hamel A, Westenbrink TG, Hrabarchuk B, MacDonald R, Ramsey E, Gartner JG, Pettigrew NM, Johnston B et al.: Expression of the c-myc proto-oncogene in prostatic tissue. [Review]. Prog Clin Biol Res 239: 91–112, 1987
Funa K, Nordgren H, Nilsson S: In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma. Scand J Urol Nephrol 25: 95–100, 1991
Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56: 917–930, 1989
Carter HB, Piantadosi S, Isaacs JT: Clinical evidence for an implications of the multistep development of prostate cancer. J Urol 143: 742–746, 1990
Hynes NE, Gerber HA, Saurer S, Groner B: Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem 39: 167–173, 1989
King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976, 1985
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC: Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 5: 320–327, 1992
Ware JL, Maygarden SJ, Koontz WW Jr, Strom SC: Immunohistochenmical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum Pathol 22: 254–258, 1991
Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE: p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496–499, 1992
Visakorpi T, Kallioniemi OP, Koivula T, Harvey J, Isola J: Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. Mod Pathol 5: 643–648, 1992
Sadasivan R, Morgan R, Jennings S, Austenfeld M, Van Veldhuizen P, Stephens R, Noble M: Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol 150: 126–131, 1993
Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW: Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. [Review]. J Urol 150: 1427–1433, 1993
Klotz LH, Auger M, Andrulis I, Srigley J: Molecular analysis of neu, sis, c-myc, fos, and P53 oncogenes in benign prostatic hypertrophy and prostatic carcinoma. J Urol 143: 401A, 1990
Grob MB, Schellhammer PF, Wright GL et al.: Expression of the c-erbB2 oncogene in human prostatic carcinoma. J Urol 145: 294A, 1991
Smith RG, Nag AL: Regulation of c-sis expression in tumors of the male reproductive tract. [Review]. Prog Clin Biol Res 239: 113–122, 1987
Rijnders AW, Van der Korput JA, Van Steenbrugge GJ, Romijn JC, Trapman J: Expression of cellular oncogenes in human prostatic carcinoma cell lines Biochem Biophys Res Commun 132: 548–554, 1985
Davies P, Eaton CL, France TD, Phillips ME: Growth factor receptors and oncogene expression in prostate cells. [Review]. Am J Clin Oncol 11Suppl 2: S1–7, 1988
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis CJ, Chung LK, Hsieh JT: Bel-2 expression in androgen-independent prostate carcinoma. J Urol 149: 221A, 1993
Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bel-z protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438–4445, 1995
Fearon ER, Vogelstein BA: A genetic model for colorectal tumorigenesis. Cell 61: 759–769, 1990
Seemayer TA, Cavenee WK: Biology of disease: molecular mechanisms of oncogenesis. Lab Invest 60: 585–599, 1989
Marshall CJ: Tumor suppressor genes. Cell 64: 313–326, 1991
Weinberg RA: Tumor suppressor genes. Science 254: 249–270, 1991
Romas NA, Kwan DJ: Prostatic acid phosphatase. Biomolecular features and assays for serum determination. [Review]. Urol Clin North Am 20: 581–588, 1993
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P et al.: Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705–708, 1989
Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. [Review]. Science 253: 49–53, 1991
Malkin D, Li FP, Strong LC, Fraumeni J Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233–1238, 1990
Frebourg T, Friend SH: Cancer risks from germ-line p53 mutations. J Clin Invest 90: 1637–1641, 1992
Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP, Weinberg RA: Deletions of a DNA sequence in retinoblastomas and mesenchymal inmors organization of the sequence and its encoded protein [publied erratum appears in Proc Natl Acad Sci USA 1988 Apr; 85 (7): 2234]. Proc Natl Acad Sci USA 84: 9059–9063, 1987
Mendoza AE, Shew JY, Lee EY, Bookstein R, Lee WH: A case of synovial sarcoma with abnormal expression of the human retinoblastoma susceptibility gene. Hum Pathol 19: 487–489, 1988
Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241: 353–357, 1988
T'Ang A, Varley JM, Chakraborty S, Murphree AL, Fung YK: Structural rearrangement of the retinoblastoma gene in human breast carcinoma., Science 242: 263–266, 1988
Yokota J, Akiyama T, Fung YK, Benediet WF, Namba Y, Hanaoka M, Wada M, Terasaki T, Shimosato Y, Sugimura T et al.: Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. Oncogene 3: 471–475, 1988
Varley JM, Armour J, Swallow JE, Jeffreys AJ, Ponder BA, T'Ang A, Fung YK, Brammar WJ, Walker RA: The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours [published erratum appears in Oncogene 1990 Feb: 5 (2): 245]. Oncogene 4: 725–729, 1989
Bookstein R, Shew JY, Chen PL, Scully P, Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712–715, 1990
Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee WH: Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 87: 7762–7766, 1990
Brooks JD, Bova GS, Isaacs WB: Allelic loss of the retinoblastoma gene in primary human prostatic adenocarci nomas. Prostate 26: 35–39, 1995
Donehower LA, Bradeley A: The tumor suppressor gene p53, Biochim Biophys Acta 1155: 181–205, 1993
Levine AJ: The TSGs. Ann Rev Biochem 621: 623–651, 1993
Harris CC, Hollstein M: Clinical implications of the p53 tumor-suppressor gene [see comments]. [Review]. N Engl J Med 329: 1318–1327, 1993
Takahashi T, Suzuki H, Hida T, Sekido Y, Ariyoshi Y, Ueda R: The p53 gene is very frequently mutated in small-cell lung cancer with a distinet nucleotide substitution pattern. Oncogene 6: 1775–1778, 1991
Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P et al.: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706–709, 1991
Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883–887, 1992
Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369–3373, 1993
Dinjens WN, Van der Weiden MM, Schroeder FH, Bosman FT, Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630–633, 1994
Voeller HJ, Sugars LY, Pretlow T, Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492–495, 1994
Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657–1669, 1993
Effert PJ, McCoy RH, Walther PJ, Liu ET: p53 gene alterations in human prostate carcinoma. J Urol 150: 257–261, 1993
Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151: 1276–1280, 1994
Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889–895, 1988
Brinkmann AO, Kuiper GG, Ris-Stalpers C, Van Rooij HC, Romalo G, Trifiro M, Mulder E, Pinsky L, Schweikert HU, Trapman J: Androgen receptor abnormalities. [Review]. J Steroid Biochem Mol Biol 40: 349–352, 1991
Faber PW, Van Rooij HCJ, Schipper HP, Brinkmann AO, Trapman J: Two different, overlapping pathways of transcription initiation are active on the TAT-less human androgen receptor promoter. J Biol Chem 268: 9296–9301, 1993
Rundlett SE, Wu XP, Miesfeld RL: Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 4: 708–714, 1990
Jenster G, Van der Korput HA, Van Vroonhoven C, Van der Kwast TH, Trapman J, Brinkmann AO: Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization, Mol Endocrinol 5: 1396–1404, 1991
Luisi BF, Xu WX, Otwinowski Z, Feedman LP, Yamamoto KR, Sigler PB: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA Nature 352: 497–505, 1991
Picard D, Kumar V, Chambon P, Yamamoto KR: Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul 1: 291–299, 1990
Tilley WD, Wilson CM, Marcelli M, McPhaul MJ: Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 50: 5382–5386, 1990
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R. Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401–406, 1995
Klocker H, Culig Z, Kaspar F, Hobisch A, Eberle J, Reissigl A, Bartsch G: Androgen signal transduction and prostatic carcinoma. [Review]. World J Urol 12: 99–103, 1994
Barrack ER, Bujnovsky P, Walsh PC: Subcellular distribution of androgen receptors in benign hyperplastic and malignant prostatic tissues: characterisation of salt resistant receptors. Cancer Res 43: 1107–1116, 1983
Kyprianou N, Davies P: Association states of androgen receptor nuclei of human benign hypertrophic prostate. Prostate 8: 363–380, 1986
Ekman P, Brolin J: Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma. Prostate 18: 147–153, 1991
Masai M, Sumiya H, Akimoto S, Yatani R, Chang CS, Liao SS, Shimazaki J: Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17: 293–300, 1990
Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46: 759–765, 1993
Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 89: 6319–6323, 1992
Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861–2864, 1994
Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R: Genetic variation of five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12: 241–253, 1992
Sloddens HF, Oostra BA, Brinkmann AO et al.: Tyrinucleotide (GGN) repeat polymorphism in the human androgen receptor. Hum Mol Genet 2: 273, 1993
Chamberlin NL, Driver ED, Miesfield RL: The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain effect transactivation function. Nucleic Acids Res 22: 3181–3186, 1994
Irvine RA, Yu MC, Ross RK, Coetzee GA: The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55: 1937–1940, 1995
Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER: Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 198: 74–80, 1994
Byrne RL, Leung H, Neal DE: Peptide growth factors in the prostate as mediators of stromal epithelial interactions. Br J Urol 77: 627–633, 1996
Norgaard P, Hougaard S, Poulsen HS, Spang-Thomsen M: Transforming growth factor beta and cancer. [Review], Cancer Treat Rev 21: 367–403, 1995
Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, Kato M, Lee C: Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res 56: 44–48, 1996
Goldstein D, O'Leary M, Mitchen J, Borden EC, Wilding G: Effects of interferon beta ser and transforming growth factor beta on prostatic cell ines. J Urol 146: 1173–1177, 1991
Zentella A, Weis FM, Ralph DA, Laiho M, Massague J: Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol 11: 4952–4958, 1991
Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24: 4–9, 1993
Ivanovic V, Mclman A, Davis-Joseph B, Valcic M, Geliebter J: Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer [letter]. Nature Med 1: 282–284, 1995
Morton DM, Barrack ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 55: 2596–2602, 1995
Steiner MS, Barrack ER: Transforming growth factor-beta 1 overproduction in prostate cancer effects on growth in vivo and in vitro. Mol Endocrinol 6: 15–25, 1992
Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E: Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 62: 79–87, 1989
Desruisseau, Ghazarossian Ragni E, Chinot O, Martin PM: Divergent effect of TGFbetal on growth and proteolytic modulation of human prostatic cancer cell lines. Intern J Cancer 66: 796–801, 1996
Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ: Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 56: 1142–1145, 1996
Lloyd SN, Brown LL, Leake RE: Transforming growth factor-alpha expression in benign and malignant human prostatic discase. Int J Biol Markers 7: 27–34, 1992
Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JG: Expression of mRNA for cpidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 126: 151–158, 1993
Morris GL, Dodd JG: Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272–1274, 1990
Fox SB, Persad RA, Colcman N, Day CA, Silcocks PB, Collins CC: Prognostic value of c-crbB-2 and epidermal growth factor receptor in stage Al (Tla) prostatic adenocarcinoma. Br J Urol 74: 214–220, 1994
Connolly JM, Rose DP: Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line. Prostate 15: 177–186, 1989
Connolly JM, Rose DP: Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate 19: 173–180, 1991
Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM: Autonomous growth of androgenindependent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780–2785, 1991
Connolly JM, Rose DP: Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16: 209–218, 1990
Liu XH, Wiley HS, Meikle AW: Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J Clin Endocrinol Metah 77: 1472–1478, 1993
Schuurmans AL, Bolt J, Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12: 55–63, 1988
Brass AL, Barnard J, Patai BL, Salvi D, Rukstalis DB: Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. Cancer Res 55: 3197–3203, 1995
Xie H, Turner T, Wang MH, Singh RK, Siegal GP, Wells A: In vitro invasiveness of DU-145 human prostate carcinoma cells is modelated by EGF receptor-mediated signals. Clin Exp Metastasis 13: 407–419, 1995
Liu DF, Rabbani SA: Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate 27: 269–276, 1995
Jarrard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB: Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24: 46–53, 1994
Pinski J, Reile H, Halmos G, Groot K, Schally AV: Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res 54: 169–174, 1994
Pinski J, Reile H, Halmos G, Groot K, Schally AV: Inhibitory effects of analogs of utcinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 59: 51–55, 1994
Kim JH, Sherwood ER. Sutkowski DM, Lee C, Kozlowski JM: Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J Urol 146: 171–176, 1991
Cohen P, Pechl DM, Rosenfeld RG: The IGF axis in the prostate, [Review]. Horm Metab Res 26: 81–84, 1994
Kaicer EK, Blat C, Harel L: IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. Growth Factors 4: 231–237, 1991
Iwamura M, Sluss PM, Casamento JB, Cockett AT: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243–252. 1993
Pietrzkowski Z, Mudholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53: 1102–1106, 1993
Polychronakos C, Janthly U, Lehoux JF, Koutsilieris M: Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells:characterization of the receptors involved. Prostate 19: 313–321, 1991
Culig Z, Hobich A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474–5478, 1994
Koutsilieris M, Polychronakos C: Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and os teoblasts. Anticancer Res 12: 905–910, 1992
Janssen T, Kiss R, Dedecker R, Petein M, Pasteels JL, Schulman C: Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DU145, and LNCaP prostatic cancer cell lines: relationship with DNA ploidy level. Prostate 27: 277–286, 1995
Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW: Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumorstromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147: 1151–1159, 1992
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1: 944–949, 1995
Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TH, Bova GS, Simons JW: Endothelin-1 production and decreased endothin B receptor expression in advanced prostate cancer. Cancer Res 56: 663–668. 1996
Kobayashi S, Tang R, Wang B, Opgenorth T, Stein E, Shapiro E, Lepor H: Localization of endothelin receptors in the human prostate. J Urol 151: 763–766, 1994
Warner TD, de Nucci G, Vane JR: Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. Eur J Pharmacol 159: 325–326, 1989
Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F: Endothelin receptor subtype B mediates the synthesis of nitric oxide by bovine endothelial cells. J Clin Invest 91: 1367–1373, 1993
Kitasjima I, Kawahara K, Nakajima T, Sockima Y, Matsuyama T, Marnyama I: Nitric oxide-mediated apoptosis in mastocytoma. Biochem Biophys Res Commun 203: 244–251, 1994
Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses the tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181: 1333–1343, 1995
Goligorsky MS, Tsukahara H, Magazine H, Anderson TT, Malik AB, Bahou WF: Termination of endothelin signalling: role of nitric oxide. J Cell Physiol 158: 485–494, 1994
Boulanger C, Luscher TF: Release of endothelin from the porcine aorta: inhibition by endothelin-derived nitric oxide. J Clin Invest 85: 587–590, 1990
Graham CW, Lynch JH, Djakiew D: Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147: 1444–1447, 1992
Djakiew D, Pflug B, Onoda M: Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. Adv Exp Med Biol 330: 185–202, 1993
Djakiew D, Delsite R, Pflug B, Wrathall J, Lynch JH, Onoda M: Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoptastic epithelial cell line and stromal cells of the human prostate. Cancer Res 51: 3304–3310, 1991
Djakiew D, Pflug BR, Delsite R, Onoda M, Lynch JH, Arand G, Thompson EW: Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. Cancer Res 53: 1416–1420, 1993
Yang G, Wheeler TM, Kattan MW, Scardino PT, Thompson TC: Perincural invasion of prostate carcinoma cells is associated with reduced apoptotic index. Cancer 78: 1267–1271, 1996
Horigome K, Bullock ED, Johnson EM Jr: Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. J Biol Chem 269: 2695–2702, 1994
Smith RC, Litwin MS, Lu Y, Zetter BR: Identification of an endogenous inhibitor of prostatic carcinoma cell growth. Nature Med 1: 1040–1044, 1996
Cipolla BG. Ziade J. Bansard JY, Moulinoux JP, Stacrman F, Quemener V, Lobel B, Guille F: Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with MI prostate carcinoma. Cancer 78: 1055–1065, 1996
Costello LC, Franklin RB: Effect of prolactin on the prostate. [Review]. Prostate 24: 162–166, 1994
Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC: In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145 and PC3 models of the human prostate. Cancer 77: 144–149, 1996
Rana A, Habib FK, Halliday P, Ross M, Wild R, Elton RA, Chisholm GD: A case for synchronous reduction of testicular androgen, adrenal androgen and prolactin for the treatment of advanced carcinoma of the prostate [see comments]. Eur J Cancer 31A: 871–875, 1995
Heino J: Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 65: 717–722, 1996
Jewell K, Kapron-Bras C, Jeevaratnam P, Dedhar S: Stimulation of tyrosine phosphorylation of distinct proteins in response to antibody-mediated ligation and clustering of alpha 3 and alpha 6 integrins. J Cell Sci 108: 1165–1174, 1995
Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB: Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 145: 167–174, 1994
Nagle RB, Knox JD, Wolt C, Bowden GT, Cress AE: Adhesion molecules, extraccllular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 19: 232–237, 1994
Cress AE, Rabinovitz I, Zhu W, Nagle RB: The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. Cancer Metastasis Rev 14: 219–228, 1995
Cress AE, Rabinovitz I, Zhu W, Nagle RB: The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. [Review]. Cancer Metastasis Rev 14: 219–228, 1995
Nagle RB, Hao J, Knox JD, Dalkin BL, Clark V, Cress AE: Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 146: 1498–1507, 1995
Rabinovitz I, Nagle RB, Cress AE: Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metastasis 13: 481–491, 1995
Dedhar S, Saulnier R, Nagle R, Overall CM: Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane. Clin Exp Metastasis 11: 391–400, 1993
Coppolino M, Migliorini M, Argraves WS, Dedhar S: Identification of a novel form of the alpha 3 integrin subunit: covalent association with transferrin receptor. Biochem J 306: 129–134, 1995
Rossi MC, Zetter BR. Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 89: 6197–7201, 1992
Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, de Kernion JB, Belldegrun AS: In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines. Cancer 77: 1862–1872, 1996
Witkowski CM, Rabinovitz I, Nagle RB, Affinito KS, Cress AE: Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines, J Cancer Res Clin Oncol 119: 637–644, 1993
Paul R, Jarrard DF, Bussemakers MJ, Nguyen SH, Bova GS, Schalken JA, Isaacs WB: Loss of P-cadherin expression in prostate cancer. Eur Urol 30(52), 1996 (Abstract)
Isaacs WB, Bova GS, Morton RA, Busscmakers MJ, Brooks JD, Ewing CM: Genetic alterations in prostate cancer. [Review]. Cold Spring Harb Symp Quant Biol 59: 653–659, 1994
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, Debruyne FM, Isaaes WB: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 52: 5104–5109, 1992
Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG: Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 148: 1375–1380, 1996
Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jennings TA, Ingle R, Kim DN: F-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade. DNA content pathologic stage, and clinical outcome. Mod Pathol 7: 835–841, 1994
Giroldi LA, Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 12: 29–37, 1993
Umbas R, Isaac WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oostcrhof GO, Debruync FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929–3933, 1994
Bussemakers MJ, Van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaaes JT, Takeichi M, Debruyne FM, Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52: 2916–2922, 1992
Giroldi LA, Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. [Review], Cancer Metastasis Rev 12:29–37, 1993
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NF, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55: 5195–5199, 1995
Schalken JA, Smit F, Bringuier PP, van Bokhoven A, Debruyne FM, Bussemakers MJ: The role of E-cadherin mutations in bladder and prostate cancer, is E-cadherin a classical suppressor gene? J Urol 155: 339A, 1996
Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB: Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 55: 4813–4817, 1995
Birchmeier W, Behrens J: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1109: 11–26, 1994
Hulsken J, Birchmeier W, Behrens J: E-cadherin and APC compete for the intraction with beta catenin and the cytoskeleton. J Cell Biol 127: 2061–2069, 1994
Carruba G, Miceli D, D'Amico D, Farruggio R, Comito L, Montesanti A, Polito L, Castagnetta LA: Sex steroids upregulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. Biochem Biophys Res Commun 212: 624–631, 1995
Prall F, Nollau P, Neumaier M, Haubeck HD, Drzeniek Z, Helmchen U, Loning T, Wagener C: CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and mycloid cells in a wide range of normal human tissues. J Histochem Cytochem 44: 35–41, 1996
Hsich JT, Lin SH: Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. J Biol Chem 269: 3711–3716, 1994
Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT: Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 55: 1215–1220, 1995
Lin SH, Luo W, Earley K, Cheung P, Hixson DC: Structure and Iunction of C-CAMI: effects of the cytoplasmic domain on cell aggregation. Biochem J 311: 239–245, 1995
Hsich J-T, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH: Tumour suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 55: 190–197, 1995
Kleinerman DI, Zhang WW, Lin SH, Nguyen TV, von Eschenbach AC, Hsieh JT: Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res 55: 2831–2836, 1995
Wolff JM, Stephenson RN, Chisholm GD, Habib FK: Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. Eur J Cancer 31A: 339–341, 1995
Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1: 27–31, 1995
Lokeshwar VB, Lokeshwar BL, Pham HT, Block NL: Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res 56: 651–657, 1996
Folkman J, Hanahan D: Switch to the angiogenic phenotype during tumorigenesis, [Review]. Princess Takamatsu Symp 22: 339–347, 1991
Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1: 149–153, 1995
Brown LF, Yeo KT, Berse B, Morgentaler A, Dvorak, HF, Rosen S: Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. J Urol 154: 576–579, 1995
Moon SY, Yoon JH, Moon WC, Seo KK, Ki YJ: Role of angiogenesis and vascular endothelial growth factor in glandular hyperplasia of rat ventral prostate. J Urol 155(Suppl): 463A, 1996
Bertrand N, Jonea F, Moro F, Soedrello S, Malavaud B, Cussenot O, Rischman P, Sarramon JP, Toulouse JP: In vitro regulation of VEGF expression in epithelial prostatic cells by testosterone. J Urol 155(Suppl): 603A, 1996
Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, Peoples GE, Klagsbrun M: Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55: 4140–4145, 1995
Vukanovic J, Isaacs JT: Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55: 1499–1504, 1995
Chen C, Parangi S, Tolentino MJ, Folkman J: A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55: 4230–4233, 1995
Vukanovic J, Hartley-Asp B, Isaacs JT: Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 26: 235–246, 1995
Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT: Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res 53: 1833–1837, 1993
Vukanovic J, Isaacs JT: Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 55: 3517–3520, 1995
Siegal JA, Yu E, Brawer MK: Topography of neovascularity in human prostate carcinoma. Cancer 75: 2545–2551, 1995
Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC: Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 44: 869–875, 1994
Weidner N, Carroll PR, Flax J, Blumenteld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401–409, 1993
Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73: 678–687, 1994
Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo P, DeKernion J, Belldegrun A: Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 14: 1626–1636, 1996
Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 76: 453–462, 1995
Firsching A, Nickel P, Mora P, Allolio B: Antiproliferative and angiostatic activity of suramin analogues. Cancer Res 55: 4957–4961, 1995
Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer ML: Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76: 2304–2311, 1995
Mohler JL: Cellular motility and prostatic carcinoma metastases. [Review]. Cancer Metastasis Rev 12: 53–67, 1993
Stearns ME, Stearns M: Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion. [Review]. Cancer Metastasis Rev 12: 39–52, 1993
Doyle GM, Sharief Y, Mohler JL: Prediction of metastatic potential by cancer cell motility in the Dunning R 3327 prostatic adenocarcinoma in vivo model. J Urol 147: 514–518, 1992
Pienta KJ, Murphy BC, Isaacs WB, Isaacs JT, Coffey DS: Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. Prostate 20: 233–241, 1992
Stearns ME, Wang M: Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: offects of taxol. Oncol Res 6: 195–201, 1994
Stearns ME, Wang M, Stearns M: IL-10 blocks collagen IV invasion by ‘invasion stimulating factor’ activated PC-3 ML cells: upregulation of TIMP-1 expression. Oncol Res 7: 157–163, 1995
Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z: Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 53: 4493–4498, 1993
Powell WC, Knox JD, Navre M, Grogan TM, Kittelson J, Nagle RB, Bowden GT: Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res 53: 417–422, 1993
Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT: Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol 117: 144–150, 1991
Knox JD, Wolf C, McDaniel K, Clark V, Loriot M, Bowden GT, Nagle RB: Matrilysin expression in human prostate carcinoma. Mol Cardinog 15: 57–63, 1996
Baker T, Tickle S, Wasan H, Docherty A, Isenberg D, Waxman J: Serum metalloproteinases and their inhibitors: markers for malignant potential. Br J Cancer 70: 506–512, 1994
Hsu DW, Efird JT, Hedley-Whyte ET: Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 147: 114–123, 1995
Achibarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P, Goltzman D: Urokinase over-production results in increased skeletal metastasis by prostate cancer in vitro. Cancer Res 54: 2373–2377, 1994
Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ: Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior. Prostate 18: 201–214, 1991
Hille B: Ionic Channels of Excitable Membranes. Sunderland, Massachusetts: Sinauer Associates Inc. 1992
Cohen-Armon M, Sokolovsky M: Evidence for involvement of the voltage-dependent Na+ channel gating in depolarization-induced activation of G-proteins. J Biol Chem 268: 9824–9838, 1993
Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS: Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol 162: 163–171, 1995
Wonderlin WF, Woodfork KA, Strobl JS: Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. J Cell Physiol 165: 177–185, 1995
Kondo S, Yin D, Morimura T, Kubo II, Nakatsu S, Takeuchi J: Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 71: 282–289, 1995
Van Dolah FM, Ramsdell JS: Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells. J Cell Physiol 166: 49–56, 1996
Nagy P, Panyi G, Jenei A, Bene L, Gaspar R Jr, Matko J, Damjanovich S: Ion-channel activities regulate transmembrane signaling in thymocyte apoptosis and T-cell activation. Immunol Lett 44: 91–95, 1995
Arcangeli A, Becchetti A, Mannini A, Mugnai G, De Filippi P, Tarone G, Del Bene MR, Barletta E, Wanke E, Olivotto M: Integrin-mediated neurite outgrowth in neuroblastoma cells depends on the activation of potassium channels. J Cell Biol 122: 1131–1143, 1993
Isom LL, Ragsdale DS, De Jongh KS, Westenbrock RE, Reber BF, Scheuer T, Catterall WA: Structure and function of the beta 2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 83: 433–442, 1995
Becchetti A, Arcangeli A, Del Bene MR, Olivotto M, Wanke E: Response to fibroncetin-integrin interaction in leukaemia cells: delayed enhancing of a K+ current. Proc R Soc Lond B Biol Sci 248: 235–240, 1992
Watsky MA: Loss of keratocyte ion channels during wound healing in the rabbit cornea. Invest Ophthalmol Vis Sci 36: 1095–1099, 1995
Schwab A, Wojnowski L, Gabriel K, Oberleithner H: Oscillating activity of a Ca(2+)-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. J Clin Invest 93: 1631–1636, 1994
Bokvist K, Eliasson L, Ammala C, Renstrom E, Rorsman P: Co-localization of L-type Ca2+ channels and insulincontaining secretory granules and its significance for the initiation of exocytosis in mouse pancreatic B-cells. EMBO J 14: 50–57, 1995
Sheng ZH, Rettig J, Cook T, Catterall WA: Calcium de pendent interaction of N-type calcium channels with the synaptic core complex. Nature 379: 451–454, 1996
Pancrazio JJ, Tabbara IA, Kim YI: Voltage-activated K+ conductance and cell proliferation in small-cell lung cancer. Anticancer Res 13: 1231–1234, 1993
Higgins CF: Volume-activated chloride currents associated with the multidrug resistance P-glycoprotein. [Review]. J Physiol (Lond) 482: 31S–36S, 1995
Yamashita N, Hamada H, Tsuruo T, Ogata E: Enhancement of voltage-gated Na+ channel current associated with multidrug resistance in human leukemia cells. Cancer Res 46: 3736–3741, 1987
Neher E: Nobel lecture. Ion channels for communication between and within cells. [Review]. Neuron 8: 605–612, 1992
Grimes JA, Fraser SP, Stephens GJ, Downing JE, Laniado ME, Foster CS, Abel PD, Djamgoz MB, Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett 369: 290–294, 1995
Laniado ME, Lalani E-N, Fraser SP, Grimes JA, Bhangal G, Djamgoz MB, Abel PD: Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 1997 (in press)
Laniado ME, Lalani E-N, Fraser SP, Djamgoz MB, Abel PD: Outward voltage-activated K+ currents distinguish LNCaP and PC-3 cell lines. Eur Urol 30(52): 434, 1996 (Abstract)
Marino AA, Iliev IG, Schwalke MA, Gonzalez E, Marler KC, Flanagan CA: Association between cell membrane potential and breast cancer. Tumour Biol 15: 82–89, 1994
Wonderlin WF, Woodfork KA, Strobl JS: Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. J Cell Physiol 165: 177–185, 1995
Schwab A, Gabriel K, Finsterwalder F, Folprecht G, Greger R, Kramer A, Oberleithner H: Polarized ion transport during migration of transformed Madin-Darby canine kidney cells. Pflugers Arch 430: 802–807, 1995
Kyprianou N, English HF, Isaacs JT: Activation of a Ca−+-Mg++-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate 13: 103–118, 1988
Martikainen P, Isaacs JT: Role of calcium in the programmed death of rat prostatic glandular cells. Prostate 17: 175–188, 1990
Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 54: 6167–6175, 1994
Connor J, Sawezuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, Buttyan R: Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 13: 119–130, 1988
McDonnell T, von Eschenbach A, Marin M, Fernandez A, Westin P, Shi-Ming T, Brisbay S, Bick R, Buju L, McConkey D: Bel-2 confers resistance to cell death induction by androgen-ablation and chemotherapy in prostate cancer cells. J Urol 155(Suppl): 527, 1996
Steinsapir J, Socci R, Reinach P: Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Commun 179: 90–96, 1991
Batra S, Popper LD, Hartley-Asp B: Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells. Prostate 19: 299–311, 1991
Peppelenbosch MP, Tertoolen LG, De Laat SW, Zivkovie D: Ionic responses to epidermal growth factor in zebrafish cells. Exp Cell Res 218: 183–188, 1995
Misra RP, Bonni A, Miranti CK, Rivera VM, Sheng M, Greenberg ME: L-type voltage-sensitive calcium channel activation stimulates gene expression by a serum response factor-dependent pathway. J Biol Chem 26: 25483–25493, 1994
Matsunaga H, Nishimoto I, Kojima I, Yamashita N, Kurokawa K, Ogata E: Activation of a calcium-permeable cation channel by insulin-like growth factor II in BALB/c 3T3 cells. Am J Physiol 255: C442–446, 1988
Kanzaki M, Shibata H, Morgami H, Kojima I: Expression of calcium-permeable eation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells. J Biol Chem 270: 13099–13104, 1995
Huang Y, Rane SG: Potassium channel induction by the Ras/Raf signal transduction cascade. J Biol Chem 269: 31183–31189, 1994
Brown MJ, Loew LM: Electric field-directed fibroblast locomotion involves cell surface molecular reorganization and is calcium independent. J Cell Biol 127: 117–128, 1994
Carter HB, Partin AW, Coffey DS: Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. J Urol 142: 1338–1341, 1989
Carter HB, Coffey DS: Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. J Urol 140: 173–175, 1988
Ware JL, Paulson DF, Mickey GH, Webb KS: Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. J Urol 128: 1064–1067, 1982
Sherwood ER, Berg LA, Mitchell NJ, McNeal JE, Kozlowski JM, Lee C: Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol 143: 167–171, 1990
Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A: Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res 47: 281–286, 1987
Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso CL, deKernion JB, Belldegrun AS: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Human Gene Therapy 6: 1417–1426, 1995
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807–1811, 1994
Kostenuik PJ, Sanchez-Sweatman O, Orr FW, Singh G: Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the α2β1 integrin. Clin Exp Metastasis 14: 19–26, 1996
Dedhar S, Jewell K, Rojiani M, Gray V: The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. J Biol Chem 267: 18908–18914, 1992
Rokhlin OW, Cohen MB: Expression of cellular adhesion molecules on human prostate tumor cell lines. Prostate 26: 205–212, 1995
Fan K: Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefuiness of P21 protein as a predictor for bone metastasis. J Urol 139: 318–322, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lalani, EN., Laniado, M.E. & Abel, P.D. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 16, 29–66 (1997). https://doi.org/10.1023/A:1005792206377
Issue Date:
DOI: https://doi.org/10.1023/A:1005792206377